Acute promyelocytic leukemia with PML::RARA fusion

APL is one specific subtype of acute myeloid leukemia — a fast-growing cancer of the blood-forming cells inside the bone marrow. It behaves differently enough from the rest of AML, and is treated differently enough, that it is worth understanding on its own terms.

The cell involved is the promyelocyte: a white blood cell that has started growing up but has not finished. In APL these half-finished cells pile up in the marrow instead of maturing into working white cells.

Almost every case carries the same genetic accident inside the leukemia cells. Pieces of chromosome 15 and chromosome 17 swap places, welding two genes into one fused gene called PML::RARA. That fusion is what jams the cells partway through development — and it is also exactly what the two main drugs are aimed at.

If you were told years ago that you had AML-M3, or you see the letters APML, that is the same disease under an older naming system.

The PML::RARA fusion is acquired. It happens inside a blood-forming cell during a person’s life, and it sits only in the leukemia cells — which means it is not something passed to a person’s children.

Why the chromosome swap happens in the first place is not reported in any source we read. There is no lifestyle, exposure or behaviour identified in them that a person could have done differently.

The everyday symptoms come from the marrow failing to make normal blood: infections, tiredness, bruising and bleeding, sometimes weight loss. That much APL shares with the other acute leukemias.

What sets APL apart is a disturbance of blood clotting. The leukemic promyelocytes release substances that trigger clotting and dissolve clots inside blood vessels at the same time. Clinicians call it disseminated intravascular coagulation, or DIC. In plain terms, the clotting system runs itself down until there is little left to stop a bleed.

That is what makes APL dangerous early, and it is dangerous in a specific way — bleeding in places where bleeding cannot be tolerated. In the Hong Kong population study, bleeding into the brain accounted for 61 of the 144 deaths in the first 30 days. Some people present with clots rather than bleeds; the disorder cuts both ways.

The most important thing to understand about that danger is its shape in time. It is front-loaded. Early death happens most commonly within the first four days, particularly in the first 24 hours, and almost all of it happens within two weeks. After that the picture changes completely.

Treatment often begins before the diagnosis is confirmed. Cancer Research UK puts it plainly: APL can develop very quickly, so treatment usually starts straight away, before all the test results are back. Clinical guidance is to give the first drug at the earliest and slightest suspicion of APL, without waiting for genetic confirmation.

The two main drugs are not conventional chemotherapy. ATRA — all-trans retinoic acid, prescribed as tretinoin — is a relative of vitamin A taken as capsules, and instead of killing dividing cells it releases the stalled promyelocytes so they finish maturing into working white cells. Arsenic trioxide is given by drip; it also pushes the cells to mature, and additionally triggers them to self-destruct.

Arsenic is a word that alarms people, reasonably. It is poisonous at high doses; the much smaller doses used here are given under close monitoring.

Alongside the drugs, blood product support starts as soon as APL is suspected — platelets, fresh frozen plasma, cryoprecipitate — aimed at keeping the clotting system topped up while the drugs take effect.

Which regimen someone gets depends on the white cell count on the day of diagnosis. At or below 10 × 10⁹/L is standard risk, treated with ATRA and arsenic trioxide and no chemotherapy at all. Above that is high risk, treated with the same two drugs plus a chemotherapy drug, usually idarubicin, or gemtuzumab ozogamicin. So “chemotherapy-free” describes the standard-risk pathway, not everyone.

The main treatment-specific danger is differentiation syndrome. As the leukemia cells all mature at once, people can develop fever, weight gain, fluid retention, breathlessness, chest pain and confusion. It is treated with a steroid and by pausing the drug, and it can appear from the first day up to several weeks in. NCI reports it in roughly 24% to 30% of patients during induction in children.

The first days are the frightening part, and nobody is prepared for them. A suspected diagnosis means immediate admission, drugs started before results are back, repeated transfusions of platelets and clotting products, and constant monitoring. People stay in hospital for that first stretch until they are safe to go home.

Induction runs roughly eight weeks, much of it as an inpatient. This is not a few nights.

Consolidation then stretches treatment over months — further cycles of the same two drugs, some of which can often be given as an outpatient, so the second half is generally less confined than the first. In one paediatric regimen the whole course ran about nine months, with no maintenance phase afterward.

Differentiation syndrome is a specific thing to watch for and can arrive without warning. Being asked to report new breathlessness or swelling immediately is a normal part of this treatment, not a sign that something has gone wrong.

The emotional shape of APL is unusual and worth naming. The period of greatest danger sits at the very start, often before a person has absorbed what is happening at all, and then it narrows quickly. Families frequently describe the first fortnight and the rest of the treatment as two entirely different experiences.

Rarely, and for most people with APL, not at all. A marrow or blood stem cell donor plays no part in the standard treatment of newly diagnosed APL, and the guidance is explicit that a transplant is not used in a first remission at any risk level.

A transplant enters the picture only if APL comes back or does not respond. Even then, the preferred option is usually autologous — the person’s own stem cells, collected while they are in remission and given back afterward. No donor is involved in that.

A donor transplant is reserved for a narrower group still: people who do not reach a molecular remission, people whose disease returns within about a year, and people who relapse after an autologous transplant.